Protalix BioTherapeutics (PLX) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.27% |
| Dec 31, 2025 | -25.68% |
| Sep 30, 2025 | -20.00% |
| Jun 30, 2025 | 30.07% |
| Mar 31, 2025 | 39.37% |
| Dec 31, 2024 | -16.06% |
| Sep 30, 2024 | 53.98% |
| Jun 30, 2024 | 6.36% |
| Mar 31, 2024 | 19.81% |
| Dec 31, 2023 | 23.13% |
| Sep 30, 2023 | -32.41% |
| Jun 30, 2023 | 31.14% |
| Mar 31, 2023 | 29.48% |
| Dec 31, 2022 | -18.34% |
| Sep 30, 2022 | -7.59% |
| Jun 30, 2022 | 12.21% |
| Mar 31, 2022 | -7.26% |
| Dec 31, 2021 | 18.52% |
| Sep 30, 2021 | -46.05% |
| Jun 30, 2021 | 25.65% |
| Mar 31, 2021 | 16.73% |
| Dec 31, 2020 | -35.07% |
| Sep 30, 2020 | 23.39% |
| Jun 30, 2020 | -15.27% |
| Mar 31, 2020 | 10.55% |
| Mar 31, 2019 | 2.50% |
| Dec 31, 2018 | -35.03% |
| Sep 30, 2018 | -25.46% |
| Jun 30, 2018 | 1.76% |
| Mar 31, 2018 | 1.06% |
| Dec 31, 2017 | 62.10% |
| Sep 30, 2017 | 32.83% |
| Jun 30, 2017 | -24.30% |
| Mar 31, 2017 | -23.25% |
| Dec 31, 2016 | 29.54% |
| Sep 30, 2016 | 17.53% |
| Jun 30, 2016 | -14.56% |
| Mar 31, 2016 | -21.69% |
| Dec 31, 2015 | 46.03% |
| Sep 30, 2015 | 1.62% |